

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/077024 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) A61P 25/00 (2006.01)
A61K 31/713 (2006.01)

(21) International Application Number:
PCT/US2021/071785

(22) International Filing Date:
08 October 2021 (08.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/089,406 08 October 2020 (08.10.2020) US

(71) Applicant: DICERNA PHARMACEUTICALS, INC.
[US/US]; 75 Hayden Avenue, Lexington, Massachusetts
02421 (US).

(72) Inventors: OSBORN, Maire; c/o Dicerna Pharmaceu-
ticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US). GRIM, Travis; c/o Dicerna Pharmaceuticals,
Inc., 75 Hayden Avenue, Lexington, Massachusetts 02421
(US).

(74) Agent: REID, Andrea L.C. et al.; Dechert LLP, One Inter-
national Place, 40th Floor, 100 Oliver Street, Boston, Mass-
achusetts 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: SELECTIVE DELIVERY OF OLIGONUCLEOTIDES TO GLIAL CELLS




FIG. 1

(57) Abstract: The present disclosure relates to oligonucleotides for selective reduction of levels of target RNA expression and/or proteins expressed in glial cells, and related methods of delivering such oligonucleotides into glial cells.

[Continued on next page]

WO 2022/077024 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*